MINYANVILLE ORIGINAL Bristol-Myers Squibb
(BMY) just gave Gilead Sciences
(GILD) a huge lead in the competition for a better hepatitis C drug.
The big drug maker suspended a study of what was believed to be a promising experimental treatment for the liver-wasting virus. “This voluntary action was taken to protect patient safety based on the emergence of a serious safety issue,” Bristol-Myers says in a statement. “The cause of the safety issue and any potential relationship to study drug are unknown at this time.”
Shares of Bristol-Myers dropped 7% to $33.10 in morning trading Thursday, while Gilead jumped more than 8% to $58.13. Shares of rival hepatitis drug developers also rose. Vertex Pharmaceuticals
(VRTX) jumped 3% to $50.54. Idenix Pharmaceuticals
(IDIX) initially rose but was down less than 1% to $8.26 in late-morning trading.
Gilead was already considered to be leading the pack of rivals working on better hepatitis treatments, but Bristol-Myers was in the thick of the race after making a sizable acquisition earlier this year. (See Bristol-Myers Enters Hepatitis Drug Race With $2.5 Billion Takeover of Inhibitex
“This setback derails Bristol-Myers’ development plans for combination therapies and extends Gilead’s lead in the race,” Stifel Nicolaus analyst Joel Sendek says. He rates Gilead a buy with a 12-month price target of $60.
Other analysts say the development is a major blow to Bristol-Myers.
“This serious setback to a key pillar of Bristol-Myers’ long-term growth strategy makes it difficult for us to recommend that investors put new money to work at (the company’s) current valuation,” Leerink Swann analyst Seamus Fernandez says in a note. The analyst lowered his rating on the stock from to a hold from a buy.
Millions of Americans have chronic hepatitis C infections. While Vertex and Merck
(MRK) introduced vastly better treatments last year, there are several development programs that seek to create a drug that doesn’t require the injected therapy interferon as part of a regimen. Interferon has side effects, such as flu-like symptoms and fatigue.
Like Bristol-Myers, Gilead, Idenix, and Vertex are studying a class of drugs known as nucleotide polymerase inhibitors. These drugs target an enzyme that is needed for the hepatitis C virus to replicate. The goal is to create an oral regimen, possibly in a single pill, that doesn’t require interferon. The payoff could be a blockbuster product for whoever succeeds.
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.
Copyright 2011 Minyanville Media, Inc. All Rights Reserved.